Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278283 | 0.91 | TSHR (0.36) | LMNAPOLBKMT2AMEN1RAB9A | |
| SCHEMBL1679370 | 0.83 | EHMT2 (0.35) | EHMT2EHMT1APOBEC3GLMNAPOLB | |
| SCHEMBL27193333 | 0.81 | LMNA (0.37) | LMNAPOLBKMT2AMEN1RAB9A | |
| SCHEMBL5502675 | 0.81 | LMNA (0.36) | EHMT2EHMT1APOBEC3GLMNAPOLB | |
| SCHEMBL4184231 | 0.81 | MEN1 (0.37) | EHMT2EHMT1APOBEC3GLMNAPOLB | |
| SCHEMBL28384909 | 0.80 | MEN1 (0.41) | LMNAPOLBKMT2AMEN1RAB9A | |
| SCHEMBL30392206 | 0.80 | MEN1 (0.41) | LMNAPOLBKMT2AMEN1RAB9A | |
| SCHEMBL4445539 | 0.80 | NPC1 (0.36) | EHMT2EHMT1APOBEC3GLMNAPOLB | |
| SCHEMBL7112244 | 0.79 | EHMT2 (0.35) | EHMT2EHMT1APOBEC3GLMNAPOLB | |
| SCHEMBL278282 | 0.77 | GCK (0.39) | LMNAKMT2AMEN1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0942996-B8 | THROMBOLYTIC AGENTS WITH ANTITHROMBOTIC ACTIVITY | UNIV SOUTHERN CALIFORNIA (US) | 2007-02-21 | — | — | EP | claimed |
| EP-0942996-A1 | THROMBOLYTIC AGENTS WITH ANTITHROMBOTIC ACTIVITY | Diatide, Inc. (US) | 1999-09-22 | — | — | EP | claimed |
| WO-1998024917-A1 | THROMBOLYTIC AGENTS WITH ANTITHROMBOTIC ACTIVITY | DIATIDE, INC. (US) | 1998-06-11 | — | — | WO | claimed |
| US-20260055176-A1 | ANTI-IL-27 ANTIBODIES AND USES THEREOF | Surface Oncology, LLC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20240277863-A1 | ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES | HELIX BIOPHARMA CORPORATION (CA) | 2024-08-22 | — | — | US | disclosed |
| US-11931422-B2 | Antibody-urease conjugates for therapeutic purposes | HELIX BIOPHARMA CORPORATION (CA) | 2024-03-19 | — | — | US | disclosed |
| EP-3261678-B1 | ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES | HELIX BIOPHARMA CORP (CA) | 2020-11-11 | — | — | EP | disclosed |
| EP-3652209-A2 | AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF | Compass Therapeutics LLC (US) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019014328-A2 | AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF | COMPASS THERAPEUTICS LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20180243437-A1 | ANTI-VEGFR-2 UREASE CONJUGATES | HELIX BIOPHARMA CORP. (CA) | 2018-08-30 | — | — | US | disclosed |
| EP-3349792-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER VIA ANTAGONISM OF THE CD155/TIGIT PATHWAY AND TGF- | Compass Therapeutics LLC (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-1997025071-A9 | IMMUNOCONJUGATE FOR THE TREATMENT OF AIDS | — | 1997-11-13 | — | — | WO | disclosed |
| WO-1997025071-A2 | IMMUNOCONJUGATE FOR THE TREATMENT OF AIDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1997-07-17 | — | — | WO | disclosed |
| EP-0776338-A1 | IMMUNOCONJUGATES COMPRISING TYROSINE KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1997-06-04 | — | — | EP | disclosed |
| US-5587459-A | LINKED TO A LIGAND TARGETING A CELL SURFACE RECEPTOR; FOR TREATING CANCERS AND AUTOIMMUNE DISEASES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-12-24 | — | — | US | disclosed |
| US-5534254-A | Biosynthetic binding proteins for immuno-targeting | CHIRON CORPORATION (US) | 1996-07-09 | — | — | US | disclosed |
| WO-1996006116-A9 | IMMUNOCONJUGATES COMPRISING TYROSINE KINASE INHIBITORS | — | 1996-03-28 | — | — | WO | disclosed |
| WO-1996006116-A1 | IMMUNOCONJUGATES COMPRISING TYROSINE KINASE INHIBITORS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-02-29 | — | — | WO | disclosed |
| EP-0688327-A1 | ANALOGS FOR SPECIFIC OLIGOSACCHARIDE-PROTEIN INTERACTIONS AND USES THEREFOR | Glycan Pharmaceuticals, Inc. (US) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994020512-A2 | ANALOGS FOR SPECIFIC OLIGOSACCHARIDE-PROTEIN INTERACTIONS AND USES THEREFOR | GLYCAN PHARMACEUTICALS, INC. (US) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277863-A1 | ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES | SLC14A1, UROD, UNG | EHMT2 400/4885EHMT1 556/4885APOBEC3G 1396/4885 |
| US-20180243437-A1 | ANTI-VEGFR-2 UREASE CONJUGATES | KDR, FLT1, FLT4 | EHMT2 764/4885EHMT1 2166/4885APOBEC3G 1783/4885 |
| US-11931422-B2 | Antibody-urease conjugates for therapeutic purposes | SLC14A1, UNG, UPP1 | EHMT2 1735/4885EHMT1 1966/4885APOBEC3G 653/4885 |
| US-20260055176-A1 | ANTI-IL-27 ANTIBODIES AND USES THEREOF | IL36G, VSIG8, IL2 | EHMT2 4383/4885EHMT1 4544/4885APOBEC3G 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.